[SCHEDULE 13G] BioAge Labs, Inc. SEC Filing
ADAR1 Capital Management, LLC and Daniel Schneeberger report shared beneficial ownership of 1,937,123 shares of BioAge Labs common stock, representing 5.4% of the 35,850,037 shares outstanding. The reported position reflects holdings attributable to ADAR1 Partners, LP (1,662,162 shares) and Spearhead Insurance Solutions IDF, LLC (274,961 shares), with voting and dispositive power held jointly by the reporting persons through their advisory and managerial roles.
The filing is submitted on Schedule 13G as a passive disclosure and includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
ADAR1 Capital Management, LLC e Daniel Schneeberger dichiarano la titolarit脿 condivisa di 1.937.123 azioni ordinarie di BioAge Labs, corrispondenti al 5,4% delle 35.850.037 azioni in circolazione. La posizione comunicata riflette le partecipazioni attribuibili ad ADAR1 Partners, LP (1.662.162 azioni) e a Spearhead Insurance Solutions IDF, LLC (274.961 azioni), con i poteri di voto e dispositivi esercitati congiuntamente dalle persone che effettuano la comunicazione in virt霉 dei loro ruoli di consulenza e gestione.
La comunicazione 猫 presentata sul modulo Schedule 13G come disclosure passiva e contiene la certificazione che le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di cambiare o influenzare il controllo dell'emittente.
ADAR1 Capital Management, LLC y Daniel Schneeberger informan la propiedad compartida de 1.937.123 acciones ordinarias de BioAge Labs, que representan el 5,4% de las 35.850.037 acciones en circulaci贸n. La posici贸n declarada refleja participaciones atribuibles a ADAR1 Partners, LP (1.662.162 acciones) y a Spearhead Insurance Solutions IDF, LLC (274.961 acciones), con los poderes de voto y disposici贸n ejercidos conjuntamente por las personas que informan en virtud de sus funciones asesoras y de gesti贸n.
La presentaci贸n se realiza en el Schedule 13G como una divulgaci贸n pasiva e incluye la certificaci贸n de que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
ADAR1 Capital Management, LLC鞕� Daniel Schneeberger電� BioAge Labs鞚� 氤错喌欤� 1,937,123欤茧ゼ 瓿惦彊鞙茧 鞁れ 靻岇湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚措姅 鞙犿喌 欤检嫕 35,850,037欤检潣 5.4%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 ADAR1 Partners, LP(1,662,162欤�) 氚� Spearhead Insurance Solutions IDF, LLC(274,961欤�)鞐� 旮办澑頃橂姅 氤挫湢攵勳潉 氚橃榿頃橂┌, 鞚橁舶甓� 氚� 觳橂秳甓岇潃 氤搓碃鞚鸽摛鞚� 鞛愲 氚� 甏�毽� 鞐暊鞚� 韱淀暣 瓿惦彊鞙茧 氤挫湢頃╇媹雼�.
氤� 鞝滌稖鞚� 靾橂彊鞝� 瓿奠嫓搿滌劀 Schedule 13G鞐� 鞝滌稖霅橃棃鞙茧┌, 頃措嫻 欤检嫕鞚� 韱奠儊鞝� 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃柎 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃╇媹雼�.
ADAR1 Capital Management, LLC et Daniel Schneeberger d茅clarent la propri茅t茅 b茅n茅ficiaire conjointe de 1 937 123 actions ordinaires de BioAge Labs, repr茅sentant 5,4 % des 35 850 037 actions en circulation. La position d茅clar茅e refl猫te des participations attribuables 脿 ADAR1 Partners, LP (1 662 162 actions) et 脿 Spearhead Insurance Solutions IDF, LLC (274 961 actions), les pouvoirs de vote et de disposition 茅tant exerc茅s conjointement par les personnes d茅clarantes en raison de leurs fonctions de conseil et de gestion.
Le d茅p么t est effectu茅 sur le Schedule 13G en tant que divulgation passive et comprend une certification indiquant que les actions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
ADAR1 Capital Management, LLC und Daniel Schneeberger melden die gemeinsame wirtschaftliche Eigent眉merschaft an 1.937.123 Aktien der Stammaktien von BioAge Labs, was 5,4% der 35.850.037 ausstehenden Aktien entspricht. Die gemeldete Position spiegelt Beteiligungen wider, die ADAR1 Partners, LP (1.662.162 Aktien) und Spearhead Insurance Solutions IDF, LLC (274.961 Aktien) zuzurechnen sind, wobei Stimm- und Verf眉gungsrechte von den meldepflichtigen Personen aufgrund ihrer beratenden und leitenden Funktionen gemeinsam ausge眉bt werden.
Die Meldung erfolgt als passive Offenlegung auf Schedule 13G und enth盲lt die Best盲tigung, dass die Aktien im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht mit der Absicht, die Kontrolle des Emittenten zu ver盲ndern oder zu beeinflussen.
- Clear disclosure of the full beneficial ownership amount (1,937,123 shares) and percentage (5.4%)
- Passive intent certified (Schedule 13G filing and statement that holdings are not to influence control)
- Breakout of holdings between ADAR1 Partners, LP (1,662,162 shares) and Spearhead Insurance Solutions IDF, LLC (274,961 shares)
- Concentrated stake of 5.4% could attract market attention despite passive classification
- Shared voting/dispositive power means influence is held jointly, which may obscure who would act if coordination changed
Insights
TL;DR A passive investor reports a material but non-control 5.4% stake, notable for ownership concentration but not an active control move.
The 1,937,123-share position equals 5.4% of the 35.85 million shares outstanding, a level that can attract investor attention without triggering control presumptions because it is filed on Schedule 13G rather than 13D. The stake is economically split between ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, implying ADAR1 Capital Management acts as investment manager and Mr. Schneeberger has shared voting/dispositive power. For investors, this signals a significant passive investor presence that could influence market liquidity and shareholder composition but does not indicate an activist or takeover intent.
TL;DR Reporting structure shows indirect beneficial ownership and a certification of passive intent, reducing immediate governance risk.
The filing clarifies managerial and advisory relationships that create indirect beneficial ownership, citing ADAR1 Capital Management's advisory role and Mr. Schneeberger's managerial position. Because the filing is a Schedule 13G and includes a statement that the shares are held in the ordinary course and not to influence control, there is no regulatory implication of an intent to change governance. However, a 5.4% holder is sufficiently large to warrant monitoring for any future shifts toward active engagement or a 13D filing if intentions change.
ADAR1 Capital Management, LLC e Daniel Schneeberger dichiarano la titolarit脿 condivisa di 1.937.123 azioni ordinarie di BioAge Labs, corrispondenti al 5,4% delle 35.850.037 azioni in circolazione. La posizione comunicata riflette le partecipazioni attribuibili ad ADAR1 Partners, LP (1.662.162 azioni) e a Spearhead Insurance Solutions IDF, LLC (274.961 azioni), con i poteri di voto e dispositivi esercitati congiuntamente dalle persone che effettuano la comunicazione in virt霉 dei loro ruoli di consulenza e gestione.
La comunicazione 猫 presentata sul modulo Schedule 13G come disclosure passiva e contiene la certificazione che le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di cambiare o influenzare il controllo dell'emittente.
ADAR1 Capital Management, LLC y Daniel Schneeberger informan la propiedad compartida de 1.937.123 acciones ordinarias de BioAge Labs, que representan el 5,4% de las 35.850.037 acciones en circulaci贸n. La posici贸n declarada refleja participaciones atribuibles a ADAR1 Partners, LP (1.662.162 acciones) y a Spearhead Insurance Solutions IDF, LLC (274.961 acciones), con los poderes de voto y disposici贸n ejercidos conjuntamente por las personas que informan en virtud de sus funciones asesoras y de gesti贸n.
La presentaci贸n se realiza en el Schedule 13G como una divulgaci贸n pasiva e incluye la certificaci贸n de que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
ADAR1 Capital Management, LLC鞕� Daniel Schneeberger電� BioAge Labs鞚� 氤错喌欤� 1,937,123欤茧ゼ 瓿惦彊鞙茧 鞁れ 靻岇湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚措姅 鞙犿喌 欤检嫕 35,850,037欤检潣 5.4%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 ADAR1 Partners, LP(1,662,162欤�) 氚� Spearhead Insurance Solutions IDF, LLC(274,961欤�)鞐� 旮办澑頃橂姅 氤挫湢攵勳潉 氚橃榿頃橂┌, 鞚橁舶甓� 氚� 觳橂秳甓岇潃 氤搓碃鞚鸽摛鞚� 鞛愲 氚� 甏�毽� 鞐暊鞚� 韱淀暣 瓿惦彊鞙茧 氤挫湢頃╇媹雼�.
氤� 鞝滌稖鞚� 靾橂彊鞝� 瓿奠嫓搿滌劀 Schedule 13G鞐� 鞝滌稖霅橃棃鞙茧┌, 頃措嫻 欤检嫕鞚� 韱奠儊鞝� 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃柎 氤挫湢霅橁碃 鞛堨溂氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃╇媹雼�.
ADAR1 Capital Management, LLC et Daniel Schneeberger d茅clarent la propri茅t茅 b茅n茅ficiaire conjointe de 1 937 123 actions ordinaires de BioAge Labs, repr茅sentant 5,4 % des 35 850 037 actions en circulation. La position d茅clar茅e refl猫te des participations attribuables 脿 ADAR1 Partners, LP (1 662 162 actions) et 脿 Spearhead Insurance Solutions IDF, LLC (274 961 actions), les pouvoirs de vote et de disposition 茅tant exerc茅s conjointement par les personnes d茅clarantes en raison de leurs fonctions de conseil et de gestion.
Le d茅p么t est effectu茅 sur le Schedule 13G en tant que divulgation passive et comprend une certification indiquant que les actions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
ADAR1 Capital Management, LLC und Daniel Schneeberger melden die gemeinsame wirtschaftliche Eigent眉merschaft an 1.937.123 Aktien der Stammaktien von BioAge Labs, was 5,4% der 35.850.037 ausstehenden Aktien entspricht. Die gemeldete Position spiegelt Beteiligungen wider, die ADAR1 Partners, LP (1.662.162 Aktien) und Spearhead Insurance Solutions IDF, LLC (274.961 Aktien) zuzurechnen sind, wobei Stimm- und Verf眉gungsrechte von den meldepflichtigen Personen aufgrund ihrer beratenden und leitenden Funktionen gemeinsam ausge眉bt werden.
Die Meldung erfolgt als passive Offenlegung auf Schedule 13G und enth盲lt die Best盲tigung, dass die Aktien im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht mit der Absicht, die Kontrolle des Emittenten zu ver盲ndern oder zu beeinflussen.
FAQ
How many BioAge (BIOA) shares does ADAR1/Schneeberger report owning?
What percentage of BIOA does the 1,937,123-share position represent?
How are the 1,937,123 shares allocated between entities?
Does this filing indicate an intent to change or influence BioAge's control?
Who holds voting and dispositive power over these shares?
